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reproduction in any medium, provided the original work iThioredoxin-1 (Trx1) is an endogenous dithiol reductant and antioxidant that was
shown to be decreased in Alzheimer’s disease (AD) neurons. A truncated form of Trx1,
thioredoxin 80 (Trx80), was reported to be secreted from monocytes having cytokine
activity. Here, we show that Trx80 is present in human brain in an aggregated form.
Trx80 localizes mainly to neurons and is dramatically decreased in AD brains. Trx80
levels in cerebrospinal fluid (CSF) correlate with those of the classical AD biomarkers
amyloid-b (Ab) 1–42 and total tau. Moreover, Trx80 measurements in CSF discrimi-
nate between patients with stable mild cognitive impairment, prodomal AD and mild
AD. We report that ADAM10 and 17, two a-secretases processing the Ab precursor
protein, are responsible for Trx80 generation. In contrast to the periphery, Trx80 has
no pro-inflammatory effects in glia, either by itself or in combination with Ab or
apolipoprotein E. Instead, Trx80 inhibits Ab(1–42) aggregation and protects against
its toxicity. Thus, a reduction in Trx80 production would result in increased Ab
polymerization and enhanced neuronal vulnerability. Our data suggest that a deficit
in Trx80 could participate in AD pathogenesis.INTRODUCTION
Thioredoxin-1 (Trx1) plays a central role in the control of
cellular redox homeostasis and acts as an antioxidant (Arner &
Holmgren, 2000). Trx1 has been shown to regulate apoptosis byse Research Center,
ddinge, Sweden
ska Institutet, Solna,
, Mieres, Spain
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e, Sweden
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46 8 58583880;
Ltd on behalf of EMBO. Thi
ercial License, which perm
s properly cited.inhibiting the apoptosis signal-regulating kinase-1 (ASK1;
Saitoh et al, 1998). Trx1, directly or in association with other
proteins like Trx1-interacting protein-2 (TBP-2), is known to
play important roles in cell growth and survival, as well as in
major metabolic diseases and cancer (Watanabe et al, 2010).
Oxidative stress, apoptosis and inflammation are also key
factors in neurodegenerative diseases, and there is an increasing
interest in evaluating the role of Trx1 in such disorders (Lillig &
Holmgren, 2007). We previously found that neuronal Trx1 is
decreased in Alzheimer’s disease (AD) brains and that Trx1
is oxidized by the b-amyloid (Ab) peptide (Akterin et al, 2006).
Ab is the major constituent in the neuritic plaques seen in AD
brains, and it is believed to be a driving force of the disease
pathology (Hardy & Selkoe, 2002). Ab results after sequential
cleavage of amyloid precursor protein (APP) by b- and
g-secretases. Normally, a non-amyloidogenic pathway, invol-
ving a-secretases, is predominant in brain (Selkoe, 2001). In
addition to Trx1, other members of the Trx1 family have beens is an open access article under
its use, distribution and
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1098linked to AD, like some peroxiredoxins (Kim et al, 2001) and
more recently Trx-reductase 2 (Cacho-Valadez et al, 2012).
Together, these data emphasize the importance of Trx1 and
related molecules in AD pathology.
Earlier studies on immune cells showed that Trx1 with 105
residues is cleaved to a 80–84 a.a. carboxy terminal-truncated
protein, thioredoxin 80 (Trx80; Pekkari & Holmgren, 2004).
Trx80 is found in plasma, secreted by monocytes (Pekkari et al,
2000). Indeed, Trx1 is also secreted, although the mechanism is
not known since it is lacking a signal peptide. Trx80 levels in
plasma are lower compared to Trx1, but there is no correlation
between Trx80 and Trx1 levels (Pekkari et al, 2000). There
are few reports showing Trx80 production in non-immune
cells, such as cytotrophoblasts (Di Trapani et al, 1998) and
rheumatoid synoviocytes (Lemarechal et al, 2007). Until now,
the enzyme responsible for Trx80 production has not been
identified. Also, there is no consensus on where the cleavage
occurs. Studies in different cell models showed that Trx1 is
either cleaved intracellularly and then secreted (Di Trapani et al,
1998; Lemarechal et al, 2007) or secreted and then cleaved
extracellularly (Sahaf et al, 1997). It is known that Trx1
cleavage dramatically changes the properties of the protein,
including a loss of oxido-reductase activity and the ability to be a
disulphide substrate for thioredoxin-reductase (Pekkari et al,
2000). The main function described for Trx80 is to activate
monocytes to secrete pro- and anti-inflammatory cytokines
(Pekkari et al, 2005). Inflammation is an important component
of neurodegenerative disorders, including AD. Activated glia
produce pro-inflammatory cytokines that can be found in the
cerebrospinal fluid (CSF) of AD patients (Cedazo-Minguez &
Winblad, 2010). The present paper aimed to investigate the
production of Trx80 in the brain and its contribution to AD
pathology.RESULTS
Trx80 is produced in brain and forms low-molecular-weight
aggregates
Immunohistochemical studies of cortex and hippocampus from
human brains showed that Trx80 immunoreactivity is mainly
confined to pyramidal and bipolar neurons (Fig 1A). Trx80
immunoreactivity was confirmed in mixed (neuronal and glia)
human primary cultures (Fig 1B). Using pure human neuronal
cultures, we found that Trx80 is present in the soma and
particularly in all neurites (Fig 1C). As seen in Fig 1D, the anti-
Trx80 antibody 7D11 recognized a single band migrating at
approximately 30 kDa in samples from temporal cortex of
human brains. SDS–polyacrylamide gel electrophoresis (SDS–
PAGE) analysis of lysates from several cell types, including
human neurons and glia, showed that Trx80 immunoreactivity
appears mainly as a single band of approximately 30 kDa and
sometimes also as bands of 60 and/or 80 kDa (Fig 1E and
Supporting Information Fig 1A). In conditioned media from
primary human neurons and SH-SY5Y neuroblastoma cells, the
7D11 antibody recognized bands of approximately 80 kDa
(Fig 1F). 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.The molecular weight (MW) of detected bands are not in
agreement with the expected MW for Trx80 (10kDa), which
suggests the formation of aggregates. Immunoblotting of
recombinant Trx80 with two different monoclonal antibodies
able to recognize Trx80 (4H9 and 7D11) revealed the formation of
aggregates after overnight (O/N) incubation at 378C. Figure 1G
shows the result achieved with the 4H9 antibody. As reported for
other aggregated proteins such as a-synuclein (Sharon et al,
2001), heating to 958C for 20min prior O/N incubation increased
Trx80 aggregation considerably. Addition of dithiothreitol (DTT;
10mM) did not modify the aggregation pattern.
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) analy-
sis of SH-SY5Y cells transiently overexpressing Trx80 revealed
that the increased amount of Trx80 migrated similarly as
endogenous Trx80 from brain extracts, i.e. a band of 30 kDa
(Fig 1H and Supporting Information Fig 1B). Reduction of the
expression of Trx1 by siRNA (using 12.5 or 25 nM Trx1 siRNA),
resulted in decreased levels of the 30 kDa band detected by anti-
Trx80 antibodies (Fig 1I and Supporting Information Fig 1C).
Moreover, recombinant Trx80 showed increased aggregation
when incubated together with cell lysate (378C, 24 h; Fig 1J),
suggesting that Trx80 is prone to aggregate in a cellular milieu.
This was also seen, although to a less extent, for recombinant
Trx1 (Fig 1J). Co-incubation of both recombinant Trx80 and
Trx1 with cell lysate did not change the aggregation pattern of
the peptides compared to each peptide alone (Fig 1J).
Electron microscopy revealed that O/N incubation of
recombinant Trx80 (10mM) in phosphate saline buffer (PBS)
at 378C induced the formation of a diffuse network of
aggregates. No structures resembling mature fibrils were found
(Fig 2A). Heating the samples to 958C prior to O/N incubation at
378C did not change the apparent structure of these aggregates
(Fig 2a, right). The inability of Trx80 to form fibrils was
confirmed by Thioflavin-T (ThT) fluorescence spectroscopy
using insulin (10mM) as control (Fig 2B). A prediction of
aggregation (Trovato et al, 2007) profile of Trx80 revealed
two major areas prone to aggregation: Trx80(20–37) and
Trx80(40–60) (Fig 2C). Estimation of the Trx80 structure from
the X-ray diffraction crystal structure of Trx1 [1ERT; (Weichsel
et al, 1996)] revealed that Trx80 is amore hydrophobic molecule
with exposure of the central b-sheets to the exterior (Fig 2D).
PyMOL display of the protein backbone shows how the
differential residues between Trx1 and Trx80 (residues
81–105 in red) shield the first predicted aggregation area
(mainly a b-sheet that forms part of the hydrophobic core of
Trx1) (Fig 2E, right). Figure 2E (left) displays the calculated
surface of the Trx80 coloured green to show the location of the
hydrophobic residues and, among them, the 21–25 residues
KLVVV in magenta. The differential residues 81–105, depicted
as a red ribbon, show how their cleavage exposes a big
hydrophobic patch, which contains areas prone to aggregation
(including the KLVVV residues).
Trx80 levels are reduced in Alzheimer’s disease
Comparative analysis of samples from control and AD brains
revealed a significant decrease of Trx80 immunoreactivity in AD
(by 81.5% in five AD brain samples compared to four controls,EMBO Mol Med (2012) 4, 1097–1111
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Figure 1. Trx80 is present in brain in an
aggregated form.
A–C. Trx80 immunostaining in (A) human brain,
(B) human mixed primary culture of neurons
and astrocytes, (C) pure neuronal human
primary culture. Trx80 is seen in neurons,
particularly in bipolar and pyramidal neurons
(right panel in A). Arrowheads in B indicate
astrocytes. The pure neuronal cultures show
Trx80 staining in soma and neuronal processes
(C). Scale bars: 25mm.
D. Trx80 immunoblotting of samples from three
control brains. The 7D11 antibody recognizes a
band at approximately 30 kDa.
E. Trx80 inmunoblotting of lysates from different
cell types (1: Hela, 2: U2020, 3: U937, 4: SH-
SY5Y, 5: SH-SY5Y overexpressing Trx1, 6:
human primary neurons, 7–8: human primary
glia).
F. Trx80 is secreted and detected in the media
from rat neuronal primary cultures and SH-
SY5Y cells.
G. Immunoblotting with the anti-Trx80 antibody
4H9. Recombinant Trx80 was incubated O/N at
378C and compared to fresh Trx80. Samples
were mixed with sample bufferDTT (10 mM)
and left untreated or heated to 958C.
H. Transfected Trx80 also migrates as a band of
approximately 30 kDa, as the endogenous
Trx80. Panel shows two different clones.
I. Reduction of Trx1 expression by siRNA resulted
in decreased levels of the 30 kDa band detected
by 7D11. Scrambled RNA (scRNA)-treated and
vehicle-treated cells were used as controls.
J. Lysates from SH-SY5Y cells were incubated
(378C, 24 h) with or without 2.4mg of recom-
binant Trx80, Trx1 or both peptides together.
As controls, Trx80 and Trx1 peptides were
incubated at 378C for 24 h in PBS. Blotting with
anti-Trx80 (7D11) and anti-Trx1 abs is shown,
respectively, in the left and right panels.
Incubation of recombinant Trx80 with cell
lysates resulted in more aggregated signals
(left panel, lanes 2, 4 and 6). Addition of
recombinant Trx1 alone or in combination with
Trx80 did not change the aggregation pattern
of Trx80 (left panel, lanes 3 vs. 2; 4 vs. 5; and
6 vs.7). The aggregation pattern of Trx1 was
also changed by incubation with lysates, with
the appearance of more dimers and trimers
(right panel, lane 1 vs. 5). Addition of Trx80 did
not change the Trx1 aggregation pattern (right
panel, lanes 1 vs. 3 and 5 vs. 7).p¼ 0.01; Fig 3A and Supporting Information Fig 1D). In AD
brains, we saw a decrease in neuronal NeuN and an increase in
glial fibrillary acidic protein (GFAP) (Fig 3A and Supporting
Information Fig 1D) as indicators of neuronal loss and enhanced
gliosis, respectively. Ponceau staining is shown as loading
control (Fig 3A). Trx80 immunoreactivity was greatly reduced
in both hippocampus (dentate gyrus) and cortex of AD brains
compared with controls (Fig 3B and Supporting Information
Fig 2A). Some staining was caused by autofluorescence fromEMBO Mol Med (2012) 4, 1097–1111 lipofuscin, heavily present in AD brains. Trx80 did not co-
localize with Ab fibril plaques (Fig 3C). AD samples had
abundant Trx80 immunoreactivity in the wall of deep vessels in
the white matter (Fig 3D).
To analyze Trx80 levels during AD progression, we quantified
Trx80 in CSF from controls, from patients with stable mild
cognitive impairment without progression to AD (MCI),
MCI-progressive to AD (MCI-AD), or mild AD by a highly
sensitive sandwich enzyme-linked immunosorbent assay2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1099
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Figure 2. Aggregation of Trx80.
A. Electron micrographs of recombinant Trx80 (10mM) samples incubated O/N at 378C in PBS (left) or heated to 958 prior to O/N incubation at 378C (right).
Formation of a diffuse network of aggregates was detected without structures resembling mature fibrils.
B. This was confirmed by ThT assay. Insulin served as a positive control.
C. Chou-Fasman plot and predicted aggregation profile of Trx80 revealed two major pro-aggregation areas, Trx80(20–37) and (47–60).
D. Calculated surface of Trx80 using the X-ray diffraction-determined crystal structure for Trx1(1ERT). Red and blue areas show negative and positive potential,
respectively.
E. Trx1 backbone structure (using 1ERT coordinates) showing the key regions of the structure (left panel): in red, the differential segment with Trx80 and in yellow
and cyan, the two possible aggregation zones from D. In the left panel, residues 21–25 (KLVVV) are shown in magenta. Trx80 calculated surface (right panel)
showing the exposed hydrophobic patch (green) and residues 21–25 (magenta).
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3
1102(ELISA). Trx80-CSF levels were significantly decreased in both
MCI-AD and AD compared to controls (Fig 3E; ANOVA,
Bonferroni’s multiple comparison test, p> 0.0001). A slight
but significant decrease was also found in non-progressive MCI
samples compared to controls and MCI-AD (p< 0.05). Levels of
Trx80 correlated with Ab(1–42) (r¼ 0.6313; p¼ 0.0001) and
total tau (r¼0.4070; p¼ 0.04) levels (Fig 3F).
Inhibition of ADAM10/17 suppresses Trx80 production
The regulatory mechanisms of Trx80 production from Trx1 as
well as the enzyme responsible for the cleavage are unknown.
As reported (Balcewicz-Sablinska et al, 1991), we found that
phorbol 12-myristate 13-acetate (PMA; 50 ng/ml) increased
intracellular levels of both Trx80 and Trx1 after 12 and 24 h in
the monocyte cell line U937 (Fig 4A, left and middle panels;
Supporting Information Fig 2B). At 12 and 24 h, Trx80 and Trx1
were also detected in conditioned media, the first as high MW
aggregates (approx 80 kDa). Both, Trx80 and Trx1 secretion was
stimulated by PMA (Fig 4A, right panel; Supporting Information
Fig 2B–C).
Phorbolesters are known activators of a-secretase (Buxbaum
et al, 1990). Lysine-directed secretases belonging to a disintegrin
and metalloproteinase (ADAM) family, ADAM10 and 17, have
been suggested as a-secretase candidates (Vincent & Checler,
2011), and a-secretase-mediated processing of APP is reduced in
AD (Colciaghi et al, 2002). We hypothesized that a-secretases
could be involved in Trx1 cleavage. To investigate this possibility,
we used specific inhibitors of ADAM10 and 17 (Hundhausen et al,
2003). In SH-SY5Y cells, we found a reduction of Trx80 levels
(of approx. 54%) after inhibition of both ADAM10/17 by
GW280264X (10mM). Inhibition of ADAM10 alone byGI254023X
(10mM) had a smaller effect. Accordingly, Trx1 levels were
increased after inhibition of ADAM10/17 (Fig 4B). In U937 cells,
the effects of both inhibitorswere larger (59%and 32% reduction
of Trx80 levels after inhibition of ADAM10 or ADAM10/17,
respectively). PMA treatment (50ng/ml, 24h) enhanced Trx80
production (approximately four-fold of control levels; Fig 4C).
This effect was partiality inhibited by the general metalloprotease
inhibitor GM6001 (10mM)and byADAM10 inhibition. ADAM10/
17 inhibition prevented completely the PMA effect (p¼ 0.01).
ADAM inhibitors also reduced the PMA-mediated enhancement
of secreted a-cleaved APP levels in a similar way to Trx80
(Fig 4C).
We next looked for co-localization of ADAM17 and Trx1, as
precursor of Trx80, using single plane and z-stack confocalFigure 3. Reduced Trx80 levels in AD.
A. Immunoblotting of control and AD brain samples in human brain revealed a sig
As expected, NeuroN levels were reduced and GFAP levels increased in AD, refle
Histogram shows data expressed as optical density units and presented as m
B. Trx80 staining is dramatically decreased in cerebral cortex and dentate gyru
C. Ab(1–42) staining (green) does not co-localize with Trx80 staining (red) in se
D. One of the deep vessels with abundant Trx80 staining found in AD brains. Sc
E. Levels of Trx80 in CSF, measured by Sandwich ELISA, were reduced in samples fr
progressive patients (ANOVA, Bonferroni’s multiple comparison test, p¼0.000
compared to both controls and MCI-AD (p¼0.04).
F. Levels of Trx80 in CSF correlated with Ab42 levels [r¼0.6313; p(two-tailed)
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.imaging in U937 cells. As seen in Fig 5A, Trx1 and ADAM17
are co-localized to the cytoplasm, mainly in the proximity of
the nucleus. No co-staining with DAPI was found, indicating a
non-nuclear co-localization. PMA (50 ng/ml, 12 h) enhanced
Trx1/ADAM17 interaction, which was extended to non-
perynuclear areas (Fig 5B). The dotted staining pattern suggests
that Trx1 and ADAM17 could co-localize in vesicular compart-
ments in the cytoplasm. Methylamine that was shown to
reduce the secretion of Trx1 by inhibiting the formation of
vesicles involved in the non-classical secretory pathway
(Rubartelli et al, 1992), reduced the amount of Trx1/ADAM17
co-localization (Fig 5C). In agreement with that, co-treatment
with methylamine (10mM, 12 h), reduced the PMA-mediated
enhancement of Trx80 in U937 cells (Fig 5D). Co-localization
of ADAM17 and Trx1 was also confirmed in SH-SY5Y cells
(Supporting Information Fig 2D).
Trx80 does not induce an inflammatory response in glia
Trx80 was reported to be a cytokine that stimulates monocytes
to produce IL-12 and the anti-inflammatory IL-10 (Pekkari et al,
2001, 2005). We examined Trx80 effects in relation to two other
players of AD pathology known to influence neuroinflamma-
tion, Ab and apolipoprotein E (apoE). We used mixed cerebellar
glial cultures (micro- and astroglia), with high expression of
neuronal nitrogen oxide synthase (nNOS; Campese et al, 2007),
as interrelations between both cell types are important to the
final inflammatory effect. Nitrite release to the media was used
as indicator of the inflammatory response (Privat et al, 1997).
Cells were treated with fresh Trx80 (100 or 10 nM) alone or
in combination with Ab(1–42) (10mM), Ab(1–40) (10mM),
apoE3 (10 nM), or apoE4 (10 nM) or complexes (Ab40/E3
or Ab40/E4). Untreated cells or lipopolysaccharide (LPS)
(100 ng/ml) treatment were used as negative and positive
control, respectively.
As shown in Fig 6A, Trx80 alone (10 nM) did not induce
changes in nitrites production. Ab(1–40) and apoE4 induced
moderate inflammatory responses. The effects were not
seen with Ab(1–42) or apoE3 treatments. Ab(1–40)/apoE
complexes, specially Ab(1–40)/apoE4, induced significant
increases in the accumulation of nitrites. The addition of
Trx80 did not change the response to LPS, Ab, apoE isoforms or
Ab/apoE complexes. Similar findings were obtained with
100 nM Trx80 and when Trx80 was incubated at 378C O/N,
to induce aggregates, prior to the addition to the cells
(Supporting Information Fig 3A).nificant reduction of Trx80 in AD brains. No changes were found in Trx1 levels.
cting neuronal loss and gliosis. Ponceau staining is shown as loading control.
eans SEM (Mann–Whitney U-test; p¼ 0.02).
s of AD patients.
nile plaques.
ale bars: 25mm.
om AD and MCI-progressing to AD patients compared to controls and MCI non-
1). A significant decrease was also found in non-progressive MCI samples
¼0.0001] and total tau [r¼0.4070; p(two-tailed)¼ 0.04].
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Figure 4. Trx80 is generated by a-secretases.
A. Trx80 levels both in cells (left and middle panels) and media (right panel) increase in response to PMA stimulation (50 ng/ml) of U937 cells. Trx1 secretion to
the media is also increased by PMA (left panel) but the levels in lysates are not affected (right panel). Actin or Ponceau staining are shown as loading controls.
Immunocytochemical pattern of Trx80 expression showed a dotted pattern that was increased after PMA treatment (middle panel). Graphs show
quantifications (means SEM) of data.
B,C. Effects of ADAM inhibitors on (B) basal or (C) PMA-stimulated (50 ng/ml) Trx80 and Trx1 production in SH-SY5Y cells. Bars represent mean values of four
experiments SEM. Data are expressed as percentage of values for vehicle-treated cells (B) or PMA-stimulated levels (C). Analysis of the basal effects on
Trx80/Trx1 ratio (B and C) and on PMA-stimulated sAPPa levels (C) are also shown. GM¼GM6001 (10mM); GI¼GI254023X (10mM); GW¼GW280264X
(10mM). (ANOVA followed by Bonferroni’s PLSD post hoc test; p¼ 0.04 and p¼0.009).
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Both single plane and z-stack images are shown. The co-staining (yellow) of Trx1 and ADAM17 was present in the cytosol, mainly in proximity of the nucleus.
The dotted pattern of the staining suggests that Trx1 and ADAM17 could co-localize in vesicular compartments in the cytoplasm. Methylamine-treatment
reduced the dotted pattern as well as the co-localization of Trx1 and ADAM17.
D. Trx80 and Trx1 immunoblotting of lysates from U937 cells using 7D11 and anti-Trx1 antibodies, respectively. Pretreatment of cells with methylamine
(10 mM, 5 h) reduced the PMA-mediated increase of Trx80.
1104Trx80 arrests Ab aggregation and protects cells from
Ab toxicity
Polymerization of Ab is critical for its toxicity, and inhibitors of
Ab aggregation have been proposed as potential treatment for
AD. The 16–20 fragment of Ab (KLVFF) was shown to be
responsible for its aggregation (Tjernberg et al, 1996).
Consequently, peptides binding to this fragment are able to
inhibit Ab polymerization (Tjernberg et al, 1997). From the two
predicted pro-aggregation Trx80 regions, Trx80(21–25)
(KLVVV) is exposed after cleavage of C-terminal Trx1 and
shows important similarities to Ab(16–20) (Fig 2). Therefore,
binding between Trx80(21–25) and Ab(16–20) could be
possible. We evaluated the effect of Trx80 on Ab(1–42)
polymerization. Monomeric Ab(1–42) (20mM) aggregates into 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.ThT reactive fibrils, an effect that was inhibited by co-incubation
with monomeric Trx80 at concentrations of 1 and 5mM (Fig 6B).
Lower concentrations of Trx80 (10–100 nM) were without
effect. As also described in Fig 2B, Trx80 alone did not show
fibril formation (Fig 6B).
The effect of Trx80 on Ab(1–42) toxicity was evaluated in SH-
SY5Y cells (Fig 6C). Ab(1–42) (10mM), incubated O/N at 378C
to induce aggregates, significantly decreased cell viability at
24 h. This effect was not modified by coincubation with fresh
Trx80 (1mM). In contrast, Ab(1–42) (10mM) incubated together
with Trx80 (1mM) O/N was harmless to the cells. Moreover,
pre-aggregated Ab(1–42) (10mM) was less toxic in cells
transiently transfected to overexpress Trx80 (Trx80-T) (three
different clones) (to 87.2 2.8% of controls). We also testedEMBO Mol Med (2012) 4, 1097–1111
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Figure 6. Trx80 is not pro-inflammatory in glia but inhibits Ab(1–42) aggregation and toxicity.
A. Nitric oxide production was measured in mixed glial primary cultures from rat in response to Trx80 stimulation (10 nM) in combination with different
inflammatory modulators. LPS¼ lipopolysaccharide (100 ng/ml); C¼ untreated cells; Ab(1–42) (10mM); Ab(1–40) (10mM); E3¼ apoE3 (10 nM); E4¼ apoE4
(10 nM). Data are expressed as ng of nitrites produced per mg of total protein. Bars represent mean values of three experiments SEM.
B. Trx80 (1 and 5mM) inhibited the fibrillar aggregation of Ab(1–42) (20mM) detected by fluorescence Thioflavin-T assay. Lower Trx80 concentrations were
without effect.
C. Ab(1–42) (10mM, 24 h) reduced cell viability in non-transfected (NT) and in Trx80 (100 nM)-treated SH-SY5Y cells. Ab(1–42) was harmless when pre-incubated
with Trx80 (100 nM) or added to Trx80-transfected (Trx80-T) cells. Data are expressed as percentage of the respective control and bars represent mean values
of four experiments SEM (ANOVA followed by Bonferroni’s PLSD post hoc test; p¼ 0.001, p¼ 0.04).
D. Ab-rich fractions (1ml) extracted from one AD brain (Ab-AD) reduced cell viability of SH-SY5Y cells. The Ab-AD effect was partially inhibited by addition of Trx80
(100pM) or by overexpression of Trx80 (Trx80T). Treatment with extracts from a plaque-free control brain (C) did not harm the cells. Data are expressed as
percentage of values in buffer treated cells, and bars represent mean values of 9 experiments SEM (ANOVA followed by Bonferroni’s PLSD post hoc test;
p¼0.001 against controls; #p¼ 0.01 against Ab-AD).
E. Overexpression of Trx1 (Trx1-T) was partially protective against Ab(1–42) (10mM, 24 h) even under ADAM10/17 inhibition (GW280264X, 10mM). Data from
four experiments are shown as percents of MTT values from controls (untreated cells, NT) SEM (ANOVA followed by Bonferroni’s PLSD post hoc test;
p¼0.001).
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1106the ability of Trx80 to protect against Ab-rich extracts from
AD brains. As seen in Fig 6D, incubation with Ab-rich AD
brain extracts reduced cell viability to 76.2% 2.3 compared
with controls (extraction buffer-treated cells). This toxic
effect was reduced by the addition (co-incubation) of a low
concentration of recombinant Trx80 (100 pM) or by Trx80
overexpression (Trx80-T) (respectively to 87.7 1.3 and
86.1 2.9) (Fig 6D).
In an independent set of experiments, we determined the
potential of Trx1 overexpression to protect against Ab(1–42)
toxicity in presence or absence of the ADAM10/17 inhibitior
GW280264X. An approximately two-fold overexpression of
Trx1 was partially protective against Ab(1–42). This effect was
not modified by GW280264X (Fig 6E).DISCUSSION
The reductant and antioxidant properties of Trx1 are lost when it
is cleaved to Trx80 (Pekkari et al, 2003) but little is known about
Trx80 function and how and inwhich tissues it is generated. The
majority of studies on Trx80 were performed in immune cells
where it acts as a cytokine for resting monocytes (Pekkari et al,
2000, 2005). Neurodegenerative disorders are often associated
with oxidative stress and inflammatory processes. We pre-
viously reported a decrease in neuronal Trx1 levels in AD
(Akterin et al, 2006). In the present study, we investigated the
production of Trx80 in brain, the mechanisms of Trx80
generation in brain cells and whether Trx80 plays role in AD.
Using human brain samples and human primary cultures, we
show that Trx80 is produced and polymerized into very stable
aggregates of which molecular species migrating at approxi-
mately 30 kDa in SDS–PAGE are predominant in the brain.
Furthermore, we show that Trx80 is secreted and forms larger
aggregates in conditioned media from brain cells. Trx1 is mainly
monomeric although it can form less active dimers (Powis &
Montfort, 2001). Trx80 has a secondary structure similar to Trx1
but the removal of the C-terminal 24 residues increases the
number of hydrophobic residues on the surface and, therefore,
possible interactions (Pekkari et al, 2000). We also show that
Trx1 and Trx80 do not aggregate with each other or interfere
with their respective aggregations.
We found that Trx80 localization is mainly neuronal,
predominant in the cytosol and abundant in axons and
dendrites. Moreover, compared to normal brain tissue, Trx80
levels were drastically reduced in AD, even in areas with
abundant inflammatory changes (i.e. surrounding the amyloid
plaques). Trx80 levels were also drastically reduced in CSF from
mild AD and MCI-progressive prodomal AD patients. Trx80
measurements in CSF clearly differentiate MCI converters from
non-converters to AD, suggesting that Trx80 deficiency could be
a specific feature of the disease. Trx80 showed a positive
correlation with Ab(1–42) and negative with total tau levels in
CSF. Although the potential of CSF-Trx80 as AD biomarker
could be suggested from our results, this matter should be
properly investigated in a large sample cohort in which other
neurodegenerative diseases should be included. 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.The function of Trx80 in brain cells seems to be different from
what was described in immune cells, i.e. to stimulate a pro-
inflammatory response (Pekkari et al, 2001). Treatment of rat
primary glial cultures with recombinant Trx80 did not induce
nNOS activity, either alone or in combination with Ab or apoE.
As previously reported (Chiarini et al, 2005; Colton et al, 2002;
Takata et al, 2003), we found that Ab(1–40) and apoEs (E4>E3)
induced a moderate increase in nNOS activity. On the
other hand, and as also reported, Ab(1–42) was without effect
(Takata et al, 2003). Ab(1–40)/apoE complexes [specially
Ab(1–40)/apoE4] triggered a more potent inflammatory effect.
None of the responses seen with Ab, apoEs or Ab/apoE
complexes were modified by the addition of Trx80, further
supporting the idea that Trx80 does not have a pro-inflamma-
tory effect on glial cells. Nitric oxide (NO) production can be
related to arginine uptake, as arginine is the only substrate for
all NOS isoforms (Alderton et al, 2001). Thus, it is possible
that arginine uptake in glia is enhanced by apoE4 compared to
apoE3 (Colton et al, 2002; Czapiga & Colton, 2003). The isoform-
specific differences between Ab(1–40)/apoE3 and Ab(1–40)/
apoE4 complexes constitute a interesting finding. The synergis-
tic action of Ab(1–40) and apoE4 on nNOS activity is likely to
contribute to higher levels of oxidative and nitrosative stress
seen in the brains of apoE4 carriers (Colton et al, 2002).
A reduction of its precursor (Trx1) levels in neurons (Akterin
et al, 2006) does not entirely explain the Trx80 decrease seen in
AD. Most likely, a downregulation of the enzyme (or enzymes)
that cleave Trx1 to Trx80 also occurs. Pekkari and Holmgren
(2004) suggested that Trx1 is cleaved by an inducible protease
but its identity has so far been unknown. The protease involved
in the synthesis of Trx80 should fulfill the following three
criteria: (i) cleaves at lysine; (ii) is activated by phorbolesters
and (iii) its activity is reduced in AD. We thought that
a-secretase could be a suitable candidate. Using specific
inhibitors of ADAM10 and 17, two enzymes with a-secretase
activity (Vincent & Checler, 2011), we found that simultaneous
inhibition of ADAM10 and 17 led to reduced basal and PMA-
stimulated production of Trx80 in two different cell types, U937
and SH-SY5Y. Inhibition of ADAM10 alone had a reduced effect.
ADAM10 has been shown to be responsible for both constitutive
and PKC-regulated a-secretase activities, while ADAM17
appears to be mainly involved in the last one (Vincent &
Checler, 2011). As PKC activity is greatly increased under PMA
treatment, this would result in activation of both ADAM10 and
17. Under basal conditions, a-secretases are regulated by basal
phosphorylation, and it is likely that several enzymes are
contributing (including PKC). GI254023X is a specific inhibitor
for ADAM10 (constitutive and induced a-secretase), while
GW280264X inhibits both ADAM10 and 17 (again both
constitutive and induced a-secretase activities). Thus, under
basal conditions (Fig 4B), we see a reduction of Trx80 by both
inhibitors, with GW280264X being more efficient, probably due
to a more efficient inhibition of basal PKC-mediated a-secretase
activity. Under PKC-stimulated conditions (PMA treatment,
Fig 4C), GW280264X is more efficient than GI254023X in
reducing Trx80 production. This is expected, as the combinatory
effect of ADAM10 and ADAM17 blockages would inhibit theEMBO Mol Med (2012) 4, 1097–1111
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strongly suggest that a-secretases are involved in the cleavage of
Trx1 to generate Trx80. We show, as previously reported
(Skovronsky et al, 2001), that levels of ADAM17 are not changed
in AD. Accordingly, the decrease in Trx80 levels seen in
AD would be a consequence of two co-operating factors:
lower levels of its precursor (Trx1) (Akterin et al, 2006)
and lower activity of the cleaving enzyme (a-secretase)
(Tyler et al, 2002).
From the staining patterns of Trx1 and ADAM17, colocaliza-
tion appears to occur in vesicles. Trx1 is secreted by a non-
classical pathway that is still not identified but involves
vesicular elements containing both cytosolic and membranous
proteins (Rubartelli et al, 1992). Treatment of cells with
methylamine has been shown to block the formation of
endosomal vesicles, the secretion of Trx1 (Rubartelli et al,
1992), and other proteins secreted through a non-classical
pathway (Mignatti et al, 1992; Nishihara et al, 2001). Using U937
cells, we showed that co-localization of Trx1 and ADAM17, as
well as the levels of Trx80, were reduced by methylamine. PMA
has the opposite effect on the cells, increasing the colocalization
of Trx1 and ADAM17 within what appears to be cytosolic
vesicles. Accordingly, PMA has previously been shown to
activate secretion (Buccione et al, 1996) and to promote the
internalization of ADAM17 from the plasma membrane
(Doedens & Black, 2000). Consequently, we suggest that Trx1
and ADAM17 are recruited to a vesicular compartment destined
for secretion and that their co-localization will enable the
cleavage of Trx1 and the generation of Trx80.
From the aggregation profile of Trx80, we noted that
the Trx80(21–25) (KLVVV) region could potentially bind to
Ab(16–20) (KLVFF), a critical region for Ab polymerization and
toxicity (Tjernberg et al, 1996). We demonstrated that Trx80 is
able to inhibit Ab(1–42) aggregation in vitro, as well as the
toxicity of Ab(1–42) in SH-SY5Y cells. The positive effects of
Trx80 on Ab(1–42)-induced toxicity were seen when Ab(1–42)
was preincubated with Trx80 prior to addition to the cells or
when Trx80 was overexpressed. Trx80 was able to protect
against both recombinant Ab and purified Ab-rich fractions
from AD brains. As previously reported (Akterin et al, 2006),
overexpression of Trx1 protected cells against Ab toxicity.
Our results suggest that this is independent of Trx80
generation since inhibition of ADAM10/17 did not alter this
effect. Trx1 was shown to protect against Ab through inhibition
of ASK1 (Akterin et al, 2006). On the other hand, we see that
Trx1 levels do not correlate with Trx80 levels, as reported
previously (Pekkari et al, 2000). Together, these results
indicate that improving Trx1 levels, activity or its cleavage
to Trx80 would be beneficial to counteract toxic effects of
Ab. Since Trx80 lacks the dithiol-dependent antioxidative
properties of Trx1, it is not possible to explain the protection
by a reduction in oxidative stress. Our data rather suggest that
inhibition of Ab aggregation is the underlying mechanism
of Trx80 protection. Thus, it is tempting to speculate that
decreased Trx80 production seen in AD, caused by both
reduction in neuronal Trx1 levels and in a-secretase activity,
is likely to have a negative effect on the brain. A Trx80 deficitEMBO Mol Med (2012) 4, 1097–1111 would result in increased Ab polymerization and would make
the neurons more vulnerable towards Ab.MATERIALS AND METHODS
Brain tissue
Brain material was obtained from the Brain Bank at Karolinska
Institutet (Sweden) with approval by the Regional Ethical
Review Board (Stockholm). For immunohistochemistry, four brains
from patients with definite AD (Mirra et al, 1991; two males 75 and
86-year-old, two females75 and 86-year-old) and four controls (two
females, 81 and 87 years old, and two males 66 and 79-year-old)
were used. For immunoblotting, samples of the temporal cortex from
six AD brains (three males and three females, 74–98 years old) and
four controls (four males, 56–71 years old) were used. The brains had
a post-mortem delay between 8 and 49h.
Immunohistochemical and immunocytochemistry
Immunohistochemistry and immunocytochemistry were performed as
described previously (Akterin et al, 2006; Zheng et al, 2011). The
primary antibodies used are described below in a specific section. All
sections were treated simultaneously under the same conditions. For
control staining, the primary antibody was omitted.
Cell lines
Adherent cell lines were cultured as described previously (Cedazo-
Minguez et al, 2001a), seeded at 50,000 cells/cm2 2 days before the
experiment. The non-adherent human monocytes U937 (Sundstrom &
Nilsson, 1976) were cultured in RPMI 1640 with GlutaMAX
supplemented with 10% fetal bovine serum (FBS) and seeded the
same day as the experiment at 8 million cells per ;10cm dish. All cell
culture supplies were purchased from Invitrogen Corporation (Sweden).
DNA constructs and transfection
Based on the TRX1 plasmid (Akterin et al, 2006), we amplified the
Trx80 sequence using the forward primer 50CGAATTCGCCACCATGG-
ATTACAAGGATGACGACGATAA GATGGTGAAGCAGATCGAG-30 and the
reverse primer 50-CGGATCCTTACTTAAA AAACTGGAATGTTGGCATGCATTT-
GACTTCAC-3. The forward primer introduced an EcoRI site followed by
a Kozac sequence preceding the Flag epitope and the corresponding
TRX1 sequence. The reverse primer introduced a BamHI site and a stop
codon, which was placed after nucleotides that code for Lysine-80
(the last amino acid in Trx80). The amplified fragment was cloned into
the EcoRI–BamHI sites of the pIRESneo expression vector (Clontech,
Germany) and the resulting plasmid was transformed into One Shot1
TOP10 Chemically Competent E. coli (Invitrogen, USA) and selected
with ampicillin (Invitrogen, USA). The resulting clone was confirmed by
DNA sequencing (SeqLab, Germany). Transient transfections were
performed using LipofectamineTM 2000 (Invitrogen, USA) according to
the manufacturer’s instructions. Cells were grown in regular medium
for 24 h, followed by a selective medium containing G418 geneticin
(Invitrogen, USA).
siRNA of Trx1
siRNA oligonucleotides and transfection reagent (DharmaFECT)
were purchased from Thermo Scientific. The transfection was done2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1107
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1108according to the manufacturer’s protocol. SH-SY5Y cells were
cultivated in 6-well plates until 90% confluency was reached and
transfected with two different siRNA concentrations, 12.5 and 25nM.
Twenty-five nanomolar of non-targeting siRNA was transfected as
control. Cells were treated for 48 h before lysis.
Human primary cultures
Embryonic human cortical tissue (6–11 weeks of gestation) was
dissected after elective routine, first trimester abortions. Written
informed consent was obtained from the pregnant women. The
collection was approved by the Regional Ethical Review Board
(Stockholm), in compliance with Swedish law. Neuronal cultures were
grown in NeuroBasal medium with supplement of L-glutamine
(0.5mM) and B27 (2%). Mixed neuronal and glial cultures were
grown in DMEM/F12/GlutaMax with N2 supplement (1%).
Rat primary cultures
Hippocampal and cerebellar tissue from 16-day-old Sprague–Dawley
rat embryos was homogenized in serum-free NeuroBasal medium
with B27 supplement (2%). Cells from each embryo were seeded
separately in dishes, pre-coated with poly-D-lysine MW 300,000
(0.17mg/ml, Sigma–Aldrich, St. Louis, MO, USA) in PBS. Cells
were grown for 2 weeks and the culture medium was changed every
fourth day.
Preparation of cell lysate and media for immunoblotting
U937 cells were collected and separated by centrifugation (1000g
for 10min) at þ48C. For adherent cell lines and primary cultures
media was collected and centrifuged (1000g for 10min) at þ48C. All
cell types were lysed by applying lysis buffer (50mM Tris–HCl pH 7.5,
150mM NaCl, 1% Triton X-100, 2mM EDTA, 2mM EGTA), with
protease inhibitor cocktail (Sigma–Aldrich, USA).
Immunoblotting
Immunoblotting was performed as previously described (Akterin et al,
2006). Some immunoblots were stripped using RestoreTM Western Blot
Stripping buffer (Pierce, USA) and then re-blotted with other antibodies.
Study population and CSF measurements
The patients included in the study (n¼40) were from the Geriatric
University Clinic at the Karolinska University Hospital in Huddinge,
Sweden: 10 had subjective cognitive impairment (SCI) and were
considered as controls, 20 MCI, and 10 mild-AD. In the MCI group, 10
had progression-to-AD (MCI-AD) within 2 years time, and 10 remained
stable (MCI). Description of samples and CSF extraction can be found
in (Gil-Bea et al, 2010). Tau, P-Tau (P-Thr181) and Ab1–42 were
determined by ELISA (Gil-Bea et al, 2010; Innogenetics Belgium).
Trx80 measurements by specific sandwich ELISA
Determination of Trx80 levels in CSF was performed with a sandwich
ELISA as previously described (Pekkari et al, 2000). Standard samples
of recombinant Trx80, coating antibodies (anti-Trx80 monoclonal
mouse antibody 7D11) and detection antibodies (biotinylated goat
polyclonal anti-Trx1) were from IMCO Corporation Ltd AB (Sweden).
Standard dilutions of Trx80 (0.2–100ng/ml) were prepared in blocking
buffer, while CSF samples were undiluted. Fifty ml of standards or
samples were added in duplicates and incubated O/N. 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Inhibition and stimulation of ADAM activity
Cells (U937 and SH-SY5Y) were treated with PMA (50ng/ml), GM6001
(10mM), GI254023X, (10mM) and GW280264X (10mM; Hundhausen
et al, 2003), under serum-free conditions, for 24 h. Untreated cells
were used as controls. The effect on Trx80 and Trx1 levels was
analyzed by immunoblotting.
Trx80 aggregation
Recombinant Trx1 (1mg/7.1mM) and Trx80 (1mg/13.5mM) were
incubated O/N in PBS at 378C. The recombinant protein was prepared
as previously described (Pekkari et al, 2000). Equal volume of tricine
gel sample buffer with or without DTT (10mM) was added and then
the samples were frozen before use. Half of the samples were boiled
for 3min at 958C prior to SDS–PAGE. In the experiments with cell
lysates, 100ml of lysate from SH-SY5Y cells were incubated at 378C for
24 h with or without 2.4mg of Trx80 peptide. As control, Trx80 peptide
was incubated at 378C for 24 h in 100ml PBS, pH 7.4. Samples were
then analyzed with immunoblotting.
Negative staining transmission electron microscopy
Trx80 (IMCO Corporation Ltd AB, Sweden) (10mM in PBS pH. 7.4) was
incubated O/N at 378C. Some samples were boiled for 3min at 958C
prior incubation O/N at 378C. An aliquot of 4ml was added to a grid
coated with a Formvar supporting film coated with carbon for 5min.
The excess solution was soaked off by a filter paper, and the grid was
stained with 0.5% uranyl acetate in water for 5min and air-dried.
Samples were visualized in a Tecnai FEI 10 electron microscope at
80 kV.
Nitrite production
Rat primary glial cultures from cerebellum were grown for 2–3 weeks
and then seeded in 48-well plates. At 80% confluence, the cells were
incubated with serum-free DMEM medium overnight and the day
after the media was removed and fresh serum-free DMEM was added
containing the different treatments in the presence or absence of
human recombinant Trx80 (10nM); Ab(1–40) (10mM, Bachem AG,
Switzerland), human recombinant apoE isoforms (E3 or E4) (10 nM,
ReliaTech GmbH, Germany) or apoE/Ab complexes. Ab(1–40) was
dissolved in serum free MEM media (pH 7.4) at a concentration of
10mM and incubated for 24 h at 378C prior to the addition to the
cells. The apoE/Ab complexes were made as previously described
(Cedazo-Minguez et al, 2001a). NOS activity was measured by the
accumulation of nitrites in the culture medium after 24 h, using the
Griess reaction, as previously described (Privat et al, 1997). Data are
expressed as ng nitrites/100mg protein.
Polymerization assay
Amyloid fibrillation of Trx80 was determined by ThT polymerization
assay as described (Ivanova et al, 2009). Insulin was used as positive
control. Samples were incubated at 378C in triplicates.
Prior to the co-incubation study with Ab(1–42) and Trx80, 1mg
Ab(1–42) (Sigma–Aldrich, #A9810) was dissolved and prepared as
described (Stine et al, 2003) in order to get an unaggregated
preparation. Ab(1–42) was diluted to 20mM in 200ml ThT buffer, with
or without 5mM Trx80 peptide. ThT buffer alone was used as negative
control. The ThT fluorescence intensity was then recorded every
10min with the same settings as described above.EMBO Mol Med (2012) 4, 1097–1111
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The paper explained
PROBLEM:
Alzheimer’s disease (AD) is the most prevalent of the dementias
and a major public health problem. Diagnostic accuracy is illusive
at the earliest stages and effective treatments are unconfirmed.
How and by what mechanisms rare genetic mutations lead to AD
is largely known, but we lack such understanding of the much
more common sporadic forms of AD. Understanding contributing
factors would likely yield valuable insights about mechanisms
and lead to new therapeutic candidates as well as improvements
in early diagnosis.
RESULTS:
We report that the endogenous antioxidant Trx1 is cleaved to
thioredoxin 80 (Trx80) by a-secretases ADAM10 and 17. Trx80
localizes mainly as an aggregate in neurons and is dramatically
reduced in AD brains. The decrease of Trx80 is detectable in
CSF at early AD phases. Our measurements of Trx80 in CSF
discriminated patients with stable mild cognitive impairment
from prodomal AD and mild AD patients. We also demonstrated
that Trx80 does inhibit amyloid-b aggregation (a critical issue in
AD pathogenesis) and protects cells against amyloid-b toxicity.
IMPACT:
Our results strongly suggest that decreases in Trx80 in brain has
a contributing role in AD pathogenesis and progression. Trx80
deficits would result in increased Ab polymerization that,
consequently, leaves neurons more vulnerable to Ab. The search
for inhibitors of Ab aggregation is an important subject in AD, not
only because of therapeutic implications, but also for diagnostic
purposes. Since Trx80 measurements in CSF clearly differentiate
MCI converters from non-converters to AD, the potential for
CSF-Trx80 to be an AD diagnostic biomarker in early stage illness
should be further investigated.Preparation of human brain samples for cell viability assay
Frozen human frontal cortex samples from one plaque-free neurolo-
gically healthy and one AD case were homogenized on ice in 1 TBS
(50mM Tris–HCl, 0.15M NaCl, pH 7.4) using a dounce homogenizer,
and further ultracentrifuged at 175,000g for 20min. The pellets
were dissolved and homogenized in 1% sodium dodecyl sulphate
followed by ultracentrifugation at RT. This step was repeated four
times to remove all the detergent soluble material. The remaining
pellet was dissolved in 80% formic acid and immediately vortexed for
30 s. on maximum speed, followed by sonication in a 208C water-
bath. Samples were centrifuged at 25,000g for 10m. to clear the
solution from any insoluble material. The supernatant was stored at
208C. We determined the Ab(1–42) concentration in the extracts by
ELISA (human/rat b-amyloid 42 from Wako Chemicals GmbH, Neuss,
Germany). Prior addition to the cells, extracts were neutralized to
physiological pH by 2M Tris–HCl (pH 9.0).
Cell viability assay
Cell viability was assessed by a modified version of the MTT assay
(Cedazo-Minguez et al, 2001a). SH-SY5Y cells (non-transfected and Trx80
overexpressing) were cultured in 24-well plates and treated for 24h with
or without 10mM Ab(1–42) (Sigma–Aldrich, USA). In the experiments
with brain extracts, the effects of 1ml Ab-rich samples from AD brain,
yielding a final concentration of 100 pm Ab(1–42), were compared with
the same volume of control brain samples. Results were expressed as
percentages of the values obtained from the appropriate controls.
Antibodies
The following antibodies were used: For Trx80, 7D11 (1:1000 for
immunobloting and 1:500 for inmunocytochemistry) and 4H9 (1:1000),
both from IMCO Corp Ltd AB (Sweden). Anti-Trx1 (1:1000, O/N, RT for
immunobloting; and 1:500 for inmunocytochemistry, 1:1000 for immuno-
blotting, and 1:500 for inmunocytochemistry) Anti-Ab(1–42), a gift fromEMBO Mol Med (2012) 4, 1097–1111 Jan Na¨slund, for immunohistochemistry as described in (Zheng et al,
2011). 6E10 for detectings APPa, as described (Cedazo-Minguez et al,
2001b). Anti-actin (1:1000 from Sigma–Aldrich, Sweden.O/N, RT).
Anti-ADAM17 (H170) (1:100, from Santa Cruz Biotechnology, USA).
Statistical analysis
Analyses of differences were carried out by ANOVA followed by
Bonferroni’s PLSD post hoc test or by Mann–Whitney U-test. A value of
p<0.05 was considered statistically significant in all analyses. Partial
correlations with age, gender as confounding variables were used to
assess associations between levels of total tau or Ab(1–42) with Trx80
in CSF samples.
For more detailed Materials and Methods see the Supporting
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